您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > SB705498
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
SB705498
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
SB705498图片
CAS NO:501951-42-4
包装与价格:
包装价格(元)
10mM (in 1mL DMSO)电议
5mg电议
10mg电议
50mg电议

产品介绍
SB705498 是一种有效的、选择性的和口服生物可利用的瞬时受体电位香草素 1 (TRPV1) 受体拮抗剂,pIC50 为 7.1。
Cas No.501951-42-4
化学名1-(2-bromophenyl)-3-[(3R)-1-[5-(trifluoromethyl)pyridin-2-yl]pyrrolidin-3-yl]urea
Canonical SMILESC1CN(CC1NC(=O)NC2=CC=CC=C2Br)C3=NC=C(C=C3)C(F)(F)F
分子式C17H16BrF3N4O
分子量429.23
溶解度≥ 14.5mg/mL in DMSO
储存条件Store at -20°C
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

PKi: 7.6 for human TRPV1 receptor

Vanilloid receptor-1 (TRPV1) is a nonselective cation channel, predominantly expressed by sensory neurons, playing a key role in the detection of noxious painful stimuli such as capsaicin, heat, and acid. TRPV1 antagonists may represent novel therapeutic agents for the treatment of a range of conditions including chronic pain, gastrointestinal disorders, and migraine. SB-705498 is a potent, selective and orally bioavailable TRPV1 antagonist.

In vitro: Using a Ca2+-based fluorometric imaging plate reader (FLIPR) assay, SB-705498 was shown to be a potent competitive antagonist of the capsaicin-mediated activation of the human TRPV1 receptor (pKi = 7.6) with activity at rat (pKi = 7.5) and guinea pig (pKi = 7.3) orthologs. SB-705498 caused rapid and reversible inhibition of the capsaicin (IC50 = 3 nM)-, acid (pH 5.3)-, or heat (50℃; IC50 = 6 nM)-mediated activation of human TRPV1 (at =70 mV) [1].

In vivo: Having initially demonstrated that SB-705498 showed good overall in vitro efficacy and oral bioavailability in rat, the in vivo activity of SB-705498 was investigated in the capsaicin-induced secondary hyperalgesia model9 in the rat. This model demonstrates the compound’s antagonist activity in vivo against the specific TRPV1 agonist capsaicin. As an early indicator of potential pharmacodynamic activity, SB-705498 showed excellent activity at 10 and 30 mg/kg po with good reversal of allodynia. Furthermore, SB-705498 was also shown to give 80% reversal of allodynia in the guinea pig FCA model at 10 mg/kg po [2].

Clinical trial: A randomised challenge trial showed that the 3% topical SB705498 cream was clinically well tolerated and had target specific pharmacodynamic activity. However there were no clinically significant differences on pruritus induced by either challenge agent in comparison to placebo. Thus, SB705498 is unlikely to be of symptomatic benefit for histaminergic or non-histaminergic induced itch [3].

Reference:
[1] Gunthorpe MJ, Hannan SL, Smart D, Jerman JC, Arpino S, Smith GD, Brough S, Wright J, Egerton J, Lappin SC, Holland VA, Winborn K, Thompson M, Rami HK, Randall A, Davis JB.  Characterization of SB-705498, a potent and selective vanilloid receptor-1 (VR1/TRPV1) antagonist that inhibits the capsaicin-, acid-, and heat-mediated activation of the receptor. J Pharmacol Exp Ther. 2007 Jun;321(3):1183-92.
[2] Rami HK, Thompson M, Stemp G, Fell S, Jerman JC, Stevens AJ, Smart D, Sargent B, Sanderson D, Randall AD, Gunthorpe MJ, Davis JB.  Discovery of SB-705498: a potent, selective and orally bioavailable TRPV1 antagonist suitable for clinical development. Bioorg Med Chem Lett. 2006 Jun 15;16(12):3287-91.
[3] Gibson RA, Robertson J, Mistry H, McCallum S, Fernando D, Wyres M, Yosipovitch G.  A randomised trial evaluating the effects of the TRPV1 antagonist SB705498 on pruritus induced by histamine, and cowhage challenge in healthy volunteers. PLoS One. 2014 Jul 21;9(7):e100610.